Lightnews — Scholar-powered news

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

TransplantID.Net - American Society of Transplantation @transplantidnet.bsky.social · 5h

Counseling immunocompromised patients on minimizing 🆔 risks? Don't reinvent the 🛞!

@astinfo.bsky.social @ast-idcop.bsky.social has Power2Save Safer Living Patient Information sheets! Translations and more topics in upcoming years!

transplantid.net?patient_educ...

3 3

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Joanna Schaenman, MD, PhD @jschaenmanmd.bsky.social · 5h

Highway to the donor danger zone? Please join the #TxID crew Tues 8am in B312 for 'Should I Take This Donor?' 🤔 w donor-derived infx experts Stephanie Pouch and Emily Blumberg dropping knowledge on all your donor-related q's ♥️ 🫁 🫘 @aneeshkmehta.bsky.social #IDSky @idweek.bsky.social #IDWeek2025

2 4

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 1h

📣 The #IDSA #IHCoP will be hosting the #IHCoP #TxID Networking Reception tomorrow at 5PM at the #OmniAtlantaHotel (M4 Grand Ballroom D) followed by a 👍 curated #PosterWalk. Click here 👇 to register www.surveymonkey.com/r/IHCoP2025 (or just show up!) #AllWelcome #IDWEEK2015

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 2h

🥳 A huge crowd gathered at the #IHCoP #BugHub stage to listen to #AlpanaWaghmere, #StellaRadosta & #GabrielMotoa discuss #ChallengingCases in #TxID!! #IDWEEK2025

2

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Joanna Schaenman, MD, PhD @jschaenmanmd.bsky.social · 1d

Thanks as always for these very helpful links! Great resource for both fellows and current practitioners in #TID #TxID #IDSky

TransplantID.Net - American Society of Transplantation @transplantidnet.bsky.social · 2d

For @txidfellows.bsky.social new to 🆔 in #SOT
🤷Where to begin⁉️

"CORE CURRICULUM"▶️ "INTRO SOLID ORGAN TRANSPLANT "📂
👉 intro: StatPearls
👉 drugs: @nejm.org @ast-idcop.bsky.social @cidjournal.bsky.social
👉 THE review @amjtransplant.bsky.social

transplantid.net?core_curricu...

1 1

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 10h

👍 Excellent session this morning at the #BugHub by #JeremyWalker hosted by @AndreaRuff and @EmilyEichenberger on #BridigingTheGap between General & #TxID! #IHCOP #IDWEEK2025

3

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Joanna Schaenman, MD, PhD @jschaenmanmd.bsky.social · 11h

Packed house difficult mold infections - very hard to say definitively if combination therapy is useful for Mucor per Dimitrios Farmakiotis , recommended to avoid use outside of stepdown therapy etc, #IDWeek2025 @idweek.bsky.social #TxID @sarahhammond.bsky.social

1 2 3

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 1d

🥳 Awesome 2 catch up w/ #HopkinsFam @tcrowellmd.bsky.social & #AmitaGupta at #BigBash @#IDWEEK2025!!

1 3

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

UW Infectious Disease Fellowship Program @uwidfellowship.bsky.social · 1d

Prolonged applause for Dr Demetri Daskalakis, formerly of the CDC, winner of the HIV Medical Association Transformative Leader Award… #IDSky #IDWeek #IDStrong

2 28 110

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

PIDS @pidsociety.bsky.social · 1d

Walter Orenstein, MD, FPIDS, an influential figure in public health and immunization efforts, including policy and hesitancy, is the Pediatric Infectious Diseases Society (PIDS) 2025 Walter T. Hughes Distinguished Physician Award honoree.
pids.org/2025/10/19/p...

Blue slide announcing PIDS Award winner, Walter Orenstein, MD, FPIDS

Dr. Orenstein stands at the IDWeek lectern delivering acceptance remarks

1 1 9

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 1d

🙌 Congratulations to #CindySears for her receipt of the #FlemingLifetime Achievement award @ #IDWEEK2025! An amazing legacy and absolutely inspiring!! #IDWEEK2025

1 9

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · 1d

#IDWEEK is Underway!! >> #JavierMunoz kicking off #IDWEEK with selections from #Hamilton, and a call for the ID community to continue it's mission to use science to impact the world 🌎 #IDWEEK2025 #WeAreID

6

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Megan Ranney MD MPH @meganranney.bsky.social · Dec 1

A friend sent this article to me today.

It feels like a good moment to remind us: the LLM outperformed physicians on STRUCTURED cases.

Someday the AIs may perform better than us in the unstructured, messy, real-world patient encounter...but that day is not today.🩺🛟

jamanetwork.com/journals/jam...

Large Language Model Influence on Diagnostic Reasoning

This randomized clinical trial evaluates the diagnostic performance of physicians with use of a large language model compared with conventional resources.

jamanetwork.com

15 36 150

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Ricardo M. La Hoz @ricardolahozmd.bsky.social · Nov 23

This is a nice and informative prospective study of donor-derived Mycoplasma and Ureaplasmain lung transplant recipients from our Duke Colleagues. Nicely done Patrick Tam! #TxID #IDSky www.amjtransplant.org/article/S160...

Donor-derived Mycoplasma and Ureaplasma infections in lung transplant recipients: A prospective study of donor and recipient respiratory tract screening and recipient outcomes

Mycoplasma hominis and Ureaplasma species are urogenital mollicutes that can cause serious donor-derived infections in lung transplant recipients. Best practices for mollicute screening remain unknown...

www.amjtransplant.org

1 10 30

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · Nov 20

🔥BALANCE RCT🔥
74 hospitals in 7 countries
3,608 patients
A 7-day course of antibiotics for hospitalized patients with bloodstream infections was non inferior to 14d within a 4% prespecified margin for mortality at 90 days #idsky
www.nejm.org/doi/full/10....

Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | NEJM

Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In a multicenter, non...

www.nejm.org

10 29 74

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · Nov 21

💉 For my #PedsTID friends >> wondering if folks are advocating multiple doses of the 2024-2025 COVID19 booster for your previously fully 💉 #Immunocompromised 👶? If so, how many more? 🙏 www.cdc.gov/mmwr/volumes...

Use of 2024-2025 COVID-19 Vaccines ...

This report describes the Advisory Committee on Immunization Practices’ recommendations for the 2024-25 COVID-19 vaccines.

www.cdc.gov

1 3

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · Nov 18

🆕️🔥Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Ofﬁcial American Thoracic Society Clinical Practice Guideline #idsky
www.atsjournals.org/doi/abs/10.1...

4 6 18

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Transplant Infectious Disease Journal @thetxidjournal.bsky.social · Nov 17

Got a cool #TxID case?

Let @maricarmalinis.bsky.social know! See below for more details.

Maricar Malinis @maricarmalinis.bsky.social · Nov 16

The TTS-TID are always on the look out for interesting and challenging Transplant ID cases. Please submit your case for consideration onlinelibrary.wiley.com/page/journal...

7 13

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · Nov 18

👍Fantastic study 👀 at whether #shorterisbetter in Neutropenic Bacteremia in adults. >80% GNB with almost 18% MDRO, profound neutropenia in 83% of enrollees & post therapy Abx PPX in 65%. Adequate source control in 70%-100%. No diff in relapse or ☠️ if <10 vs > 10 ABX days. #IDSky #TIDSky

Transplant Infectious Disease Journal @thetxidjournal.bsky.social · Nov 18

Congratulations to @nischalr3.bsky.social and his team for their paper being selected as the @thetxidjournal.bsky.social 2024 Bob Rubin Clinical Impact Awardee - this award selects the paper felt to have the biggest impact on clinical care in #TxID!

#IDSky

onlinelibrary.wiley.com/doi/10.1111/...

Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation

In the management of immunocompromised patients with neutropenia and Gram-negative bloodstream infection, short antimicrobial courses (≤10 days) had comparable propensity score-adjusted 90-day outcom...

onlinelibrary.wiley.com

1 3 16

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Michael G. Ison, MD MS @michaelisonmd.bsky.social · Nov 18

Want to learn about the treatment of RVI in immunocompromised patients?

Join us for the next @ESCMID.bsky.social ESGICH/ESGREV webinar on the treatment of RVI.

Chairs: Hans Hirsch and @michaelisonmd.bsky.social

Talks by: Pauline Vetter, Jose Luise Pinana, Fareed Khawaja

2 13 34

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Paul Sax @paulsaxmd.bsky.social · Nov 18

Excellent analysis of what happens when a clinical trial is under powered. In this example, it's the use of air purifiers in nursing homes and preventing respiratory tract infections.

Results suggest it might work. Or it might not.
@apsmunro.bsky.social

open.substack.com/pub/alasdair...

How to not be completely wrong about air filters

A new RCT of HEPA filters for residential care homes gets heads spinning

open.substack.com

3 4 27

Paul K. Sue, MDCM FIDSA, FPIDS @paulksue1.bsky.social · Nov 18

💩 Ugh -- ".. only 12.1% of NDM-producing isolates were susceptible to cefiderocol using the 2024 EUCAST version 14.0 DD breakpoint. Ceftazidime/avibactam and aztreonam synergy was seen in 87.5% of isolates tested..." In some settings, empiric use in MBL -producing isolates may be inappropriate...

Dr Neil Stone @drneilstone.bsky.social · Nov 18

New paper from my colleagues at UCLH

Nearly 70% (!!!) resistance to Cefiderocol in NDM positive bacteria.

Cefiderocol...we hardly knew ye...

Perfect timing for World Antimicrobial Awareness Week #waaw24 #IDSky

academic.oup.com/jac/advance-...

Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?

AbstractBackground. Carbapenemase-producing Enterobacterales (CPE) pose difficult therapeutic challenges. We aimed to characterize antimicrobial resistance

academic.oup.com

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Maricar Malinis @maricarmalinis.bsky.social · Nov 16

The @idsainfo.bsky.social IHCOP welcomes all who are involved in the care of immunocompromised hosts. We have a great opportunity to advance the field, build and sustain the TID workforce. Please sign
Up 🤓 my.idsociety.org/volunteeropp...

IDSA Immunocompromised Host Community of Practice

The purpose of the Immunocompromised Host Community of Practice (COP) is to create a community that

my.idsociety.org

1 11 26

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

Hensley Lab @scottehensley.bsky.social · Nov 16

The preliminary sequence from the H5N1 human case in British Columbia has been posted and it is not good news. The virus potentially has a quasispecies at HA residue 226 (H3 numbering). This is bad news because we know that mutations at residue 226 can increase binding to human receptors. 1/

210 960 2.2K

Reposted by Paul K. Sue, MDCM FIDSA, FPIDS

BK. Titanji @boghuma.bsky.social · Nov 16

Health officials in California have confirmed the first case of mpox clade I in the US. Patient is a returning traveller's who traveled to eastern Africa. This is not unexpected because the world is interconnected and there are ongoing outbreaks of clade I mpox in Africa.
apnews.com/article/mpox...

US health officials report 1st case of new form of mpox in a traveler

Health officials say they have confirmed the first U.S. case of a new form of mpox that was first seen in eastern Congo.

apnews.com

3 42 140